Peptides are short chains of amino acids held together by peptide bonds. Unlike many small-molecule compounds, those bonds are chemically reactive targets: heat, moisture, oxygen, and light can all break them. The practical consequence is that most research peptides require refrigeration during storage and a cold chain during shipping — and that requirement does not disappear once a vial is reconstituted.
Why peptides degrade
The primary degradation pathways described in the pharmaceutical literature include hydrolysis (water cleaving peptide bonds), oxidation (particularly of methionine and cysteine residues), deamidation (asparagine and glutamine residues converting to acidic forms), and aggregation (peptide chains clumping into larger, biologically inactive structures). Temperature accelerates all of these. Research published via PubMed and reviewed by manufacturers such as Bachem notes that the rate of chemical degradation roughly doubles for every 10 °C rise in temperature — a rule of thumb derived from the Arrhenius equation and widely cited in peptide formulation literature.
Lyophilized (freeze-dried) powder is more stable than liquid because removing water limits hydrolysis. Even so, lyophilized peptides are commonly stored at −20 °C or below for long-term preservation, and at 2–8 °C for shorter-term use. Reconstituted solutions — powder dissolved in bacteriostatic water or another solvent — are significantly more vulnerable: water is now present, hydrolysis can proceed, and microbial growth becomes a risk. Reconstituted vials are therefore kept refrigerated and used within a timeframe described in the product's technical documentation, which varies by compound.
Certain structural features make some peptides more sensitive than others. Sequences containing cysteine (prone to oxidation), asparagine (prone to deamidation), or multiple hydrophobic residues (prone to aggregation) are generally described in the formulation literature as higher-risk. Peptides that include disulfide bridges — structural bonds between two cysteine residues — can lose biological activity if those bridges are disrupted by improper storage.
The cold chain in shipping
A cold chain is an unbroken temperature-controlled sequence from the point of manufacture through transit to the end recipient. For peptides, this typically means insulated packaging with gel packs or dry ice, routing chosen to minimize time in transit, and labeling that communicates temperature requirements to handlers. Regulatory guidance from bodies such as the FDA and EMA for pharmaceutical-grade products specifies Good Distribution Practice (GDP) requirements that include temperature monitoring and excursion documentation. Research-use peptide vendors operate under varying standards, but the underlying chemistry is the same regardless of regulatory category.
A temperature excursion — a period during which a shipment exceeds its specified temperature range — does not automatically destroy a peptide, but it does increase cumulative degradation. The longer and warmer the excursion, the greater the potential loss of purity and potency. Third-party testing services such as Janoshik and Finnrick publish test data showing purity figures for peptide samples; lower-than-expected purity can reflect poor synthesis, poor storage, or both. Because end users cannot observe what happened during transit, an intact cold chain is the evidence-based safeguard against receiving a degraded product.
What this means for storage conditions
| State | Typical guidance (from manufacturer documentation) | Key risk if ignored |
|---|---|---|
| Lyophilized powder, long-term | −20 °C or below | Slow hydrolysis, oxidation over months/years |
| Lyophilized powder, short-term | 2–8 °C (refrigerator) | Moisture ingress if container seal is poor |
| Reconstituted solution | 2–8 °C; use within days to weeks | Rapid hydrolysis, microbial growth |
| Any form, in transit | Cold chain with monitoring | Temperature excursions accelerating all pathways |
Suppliers commonly advise keeping vials sealed until use, minimizing repeated temperature cycling (freeze-thaw cycles can stress peptide structure), and storing away from light. These recommendations appear consistently across technical datasheets from manufacturers such as Bachem and PolyPeptide Group, and are echoed in community-aggregated resources.
Peptides sold for research use are not approved for human consumption, and storage guidance referenced here is drawn from technical and manufacturing literature rather than clinical protocols.